Paul E. Wiedeman
Ohio State University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paul E. Wiedeman.
Tetrahedron Letters | 2001
David J. Madar; Hana Kopecka; Daisy Pireh; Jonathan Pease; Marina Pliushchev; Richard J. Sciotti; Paul E. Wiedeman; Stevan W. Djuric
Abstract A method for the intermolecular coupling of aryl bromides and oxazolidinones is described. Application to intermediates useful for the preparation of a known class of antibacterial agent and the synthesis of the known antibacterial oxazolidinone Dup-721 are described.
Bioorganic & Medicinal Chemistry Letters | 2008
Yaya Liu; Pamela L. Donner; John K. Pratt; Wen W. Jiang; Teresa Ng; Vijaya Gracias; Steve Baumeister; Paul E. Wiedeman; Linda Traphagen; Usha Warrior; Clarence J. Maring; Warren M. Kati; Stevan W. Djuric; Akhteruzzaman Molla
Halosalicylamide derivatives were identified from high-throughput screening as potent inhibitors of HCV NS5B polymerase. The subsequent structure and activity relationship revealed the absolute requirement of the salicylamide moiety for optimum activity. Methylation of either the hydroxyl group or the amide group of the salicylamide moiety abolished the activity while the substitutions on both phenyl rings are acceptable. The halosalicylamide derivatives were shown to be non-competitive with respect to elongation nucleotide and demonstrated broad genotype activity against genotype 1-3 HCV NS5B polymerases. Inhibitor competition studies indicated an additive binding mode to the initiation pocket that is occupied by the thiadiazine class of compounds and an additive binding mode to the elongation pocket that is occupied by diketoacids, but a mutually exclusive binding mode with respect to the allosteric thumb pocket that is occupied by the benzimidazole class of inhibitors. Therefore, halosalicylamides represent a novel class of allosteric inhibitors of HCV NS5B polymerase.
Tetrahedron Letters | 1985
Leo A. Paquette; Paul E. Wiedeman; Philip C. Bulman-Page
Abstract Pleuromutilin or tiamulin can be degraded to the important bicyclic relay compound (−)- 1 in only four steps. Various methods for achieving chemoselective functionalization of 1 are set in focus.
Tetrahedron Letters | 1985
Leo A. Paquette; Paul E. Wiedeman
Abstract Construction of the optically active lactone (−)−13, required for a proposed total synthesis of (+)-pleuromutilin, has been successfully achieved.
Archive | 2004
Zhonghua Pei; Xiaofeng Li; Kenton L. Longenecker; Hing Leung Sham; Paul E. Wiedeman
Journal of Medicinal Chemistry | 2000
Stevan W. Djuric; Nwe Y. BaMaung; Basha A; Liu H; Luly; David J. Madar; Sciotti Rj; Tu Np; Wagenaar Fl; Paul E. Wiedeman; Zhou X; Stephen J. Ballaron; Joy Bauch; Chen Yw; Chiou Xg; Thomas A. Fey; Donna M. Gauvin; Gubbins E; Gin C. Hsieh; Kennan C. Marsh; Karl W. Mollison; Pong M; Shaughnessy Tk; Sheets Mp; Morey L. Smith; James M. Trevillyan; Usha Warrior; Wegner Cd; George W. Carter
Archive | 2001
David J. Madar; Daisy Pireh; Hana Kopecka; Steven W. Djuric; Paul E. Wiedeman
Archive | 1999
Nwe Y. BaMaung; Anwer Basha; Stevan W. Djuric; Earl J. Gubbins; Jay R. Luly; Noah P. Tu; David J. Madar; Usha Warrior; Paul E. Wiedeman; Xun Zhou; Richard J. Sciotti; Frank L. Wagenaar
Journal of Medicinal Chemistry | 2006
Zhonghua Pei; Xiaofeng Li; Kenton L. Longenecker; Thomas W. von Geldern; Paul E. Wiedeman; Thomas H. Lubben; Bradley A. Zinker; Kent D. Stewart; Stephen J. Ballaron; Michael A. Stashko; Amanda K. Mika; David W. A. Beno; Michelle A. Long; Heidi Wells; Anita J. Kempf-Grote; David J. Madar; Todd S. McDermott; Lakshmi Bhagavatula; Michael G. Fickes; Daisy Pireh; Larry R. Solomon; Marc R. Lake; Rohinton Edalji; Elizabeth H. Fry; Hing L. Sham; James M. Trevillyan
Archive | 2004
Zhonghua Pei; Xiaofeng Li; Kenton L. Longenecker; Hing Leung Sham; Paul E. Wiedeman